Focal therapy for prostate cancer is emerging as a management option between active surveillance and radical treatments. In this article, we present two of the most important imaging modalities in focal therapy, multiparametric MRI (mpMRI) and ultrasonography. We review the recent advances within these two platforms.
INTRODUCTION
Following the discovery of prostate-specific antigen (PSA), the incidence of prostate cancer increased drastically, whereas cancer-specific mortality rate remained unchanged at 5% [1] . Concerns have especially been raised about the increasing detection of low-risk and intermediate-risk prostate cancer, as active treatment may not improve disease-related survival, but on the other hand may impair the quality of life significantly. Consequently, deferred treatments such as active surveillance or watchful waiting are appealing management solutions which maximize the quality of life [2] . However, these management options have their disadvantages. Biopsy sampling errors, particularly those leading to missed anterior tumors, and consequently undergrading of the tumor, is the biggest limitation of active surveillance [3] . Furthermore, repeat biopsies can result in increased costs, pain, and infections associated with increased hospitalizations [4] . A cancer diagnosis is stressful for the patient and not actively treating the disease may, in susceptible individuals, cause additional anxiety [5] . Finally, compliance is also an issue, with some studies showing as few as 53% of patients in specific subgroups comply with protocol mandated biopsy at 1 year [6] . Focal therapy can offer an alternative in patients with low-risk and intermediate-risk prostate cancer, as it offers cancer control on the one side without the side-effects of radical treatments on the other side [7, 8, 9 && ,10 & ]. For focal therapy, high end, imaging is of paramount importance. The clinician has to be positive that the targeted tumor is low-risk or intermediaterisk prostate cancer and that there is no extra capsular extension. During treatment, the clinician should be certain that the targeted tumor is being totally ablated and that outside the targeted area, no significant tumor resides. In the follow-up period, recurrences or residual tumor should be clearly recognized on imaging. The two most important imaging modalities for imaging in focal therapy are mpMRI and multiparametric ultrasound (mpUS) [11] .
In focal therapy, roughly three phases can be distinguished, each demanding a different aspect from imaging modalities. These phases include patient selection and treatment planning, treatment guidance, and follow-up after focal therapy. Definitions of these phases differ among literature, therefore we defined the definitions as used in this review:
(1) Patient selection: selection of a patient with low or intermediate prostate cancer (T2W, Gleason Score 4 þ 3, and PSA <20 ng/ml), with a target lesion confined to one lobe of the prostate. (2) Treatment guidance: real-time guidance of the focal treatment modality to the targeted lesion. (3) Follow-up: after treatment control that there is no residual tumor, or after a period of time, no recurrent tumors.
The review focuses on imaging for focal therapy in these three different phases of this treatment form.
IMAGING FOR PATIENT SELECTION
The requirements of imaging in patient selection are to identify patients with low-to-intermediate risk prostate carcinoma. Moreover, the targeted area should be identifiable (the tumor should be clearly visible on imaging). Furthermore, outside the targeted area, there should not be a significant other lesion. It is, therefore, essential to have a highresolution three-dimensional (3D) imaging technology available that identifies in high accuracy the location, size, grade, and stage of the tumor. Moreover, negative predictive value of the nonaffected prostate lobe should be high.
MRI has the potential to fulfill the strong imaging requirements for patient selection in focal therapy. MRI works with a magnetic field varying between 0.5 and 7 Tesla (T). Most systems for prostate scanning use 1.5 or 3 T. The technology relies on the detection of a radiofrequency signal emitted by excited hydrogen atoms in the body, using the energy from an oscillating magnetic field applied at the appropriate resonant frequency [12] . Until recently, the diagnostic performance of MRI was too low to implement the technology into the diagnostic workup leading to focal therapy of prostate cancer. However, evidence coming from the centers of excellence support an accurate diagnostic performance of MRI, provided that multiple sequences are used and that their outputs are combined in a mpMRI. These sequences include T2-weighted (T2W) imaging, dynamic contrast-enhanced (DCE) imaging, diffusion-weighted imaging (DWI), and sometimes proton spectroscopic imaging (MRSI) (Fig. 1) . Disagreement among experts in the field of uroradiology about the conduct, interpretation, and reporting of mpMRI have prohibited the formation of uniformly comparable literature on diagnostic accuracy and hence the formation of guidelines. Various consensus projects have therefore been initiated to standardize the conduct and reporting of mpMRI in prostate cancer [13] [14] [15] 16 & ]. The key difficulty in medical imaging research is the comparison of images to histopathology. It can be challenging to relate the images on MRI to the histopathology specimens, because of shrinkage and freehand slicing. Several solutions have been posed to overcome these challenges. Orczyk et al. [17] developed deformable histopathology mpMRI fusion computer software based on 22 landmarks in the specimens. They managed to reach an improvement in matching accuracy of 32% over rigid
KEY POINTS
Multiparametric MRI (mpMRI) is the standard of imaging in patient selection for focal therapy.
Real-time treatment guidance in focal therapy is often performed with ultrasound.
Novelties such as histoscanning, contrast-enhanced ultrasound, real-time elastography, and shear-wave elastography significantly improve cancer detection rates over grey-scale ultrasonography.
Apart from a high positive predictive value, a high negative predictive value is needed to rule out prostate cancer in the part of the prostate that is not targeted.
Standardization and automation in conduct and interpretation of imaging will lead to a higher accuracy.
comparison methods. Trivedi et al. [18] developed a 3D histopathology analysis tool using 3D printed customized moulds based on preoperative mpMRI data, corrected for shrinkage, for slicing of the histopathological specimens in exactly the same plane as the mpMRI scanning. Using these methods, Turkbey et al. [19] determined the diagnostic accuracy for the separate sequences used in mpMRI (T2W, DWI, DCE, and magnetic resonance spectroscopy) in a prospective study including 45 patients. The results are depicted in Table 1 . By using advanced histopathology matching, the validity of mpMRI accuracy research improved substantially. The same research group demonstrated that 3 T mpMRI could accurately estimate tumor volume independent of Gleason score, using this method, in 135 patients. These results are valuable in focal therapy treatment planning as well as follow-up after therapy [24 & ]. Another way to improve the diagnostic performance of MRI is to increase MRI field strength. In the prostate, only few studies have yet been done regarding 7 T mpMRI. The advantage of a higher field strength is a higher signal-to-noise ratio. Rosenkrantz et al. [25] demonstrated the feasibility of 7 T MRI in two patients with biopsy-proven prostate cancer. They demonstrated a signal-to-noise ratio gain of 2.1 at 7 T MRI vs. 3 T MRI and images showed excellent visual correlation with the radical prostatectomy specimens. Several studies demonstrated the safety and feasibility of magnetic resonance (MR) spectrocopic imaging at 7 T in patients with biopsy-proven prostate cancer. 7 T MRI rendered a well tolerated and promising technology [26, 27] .
Another promising novelty is correlated diffusion imaging (CDI). CDI takes the advantage of multiplegradient pulse strengths and timings. This not only reduces dependency on the way diffusion gradient pulses are applied, but also improves delineation between cancerous and healthy tissue. One study demonstrated an impressive improvement in area under the receiver operator characteristics (ROC) curve for CDI over normal DWI (0.9789 vs. 0.9183) in 20 patients with prostate cancer [28 && ]. The future of mpMRI lies also in standardization of conduct and interpretation and quantification of the results. These aspects will make the technology more comparable, more reproducible, and less operator dependent. Maas et al. [29] demonstrated good performance with quantitative evaluation of computed high b value diffusion-weighted MRI of the prostate. Artan et al. [30] proposed the first mechanism of automated prostate cancer localization on mpMRI. The results in the first eight patients look promising, but have to be investigated in larger trials.
Ultrasonography works with oscillating sound pressure waves that move through the body and reflect on surfaces in between dense and soft structures. In the last decennia, there were multiple advances in the field of ultrasound, which increased sensitivity and specificity of the technology for the detection of prostate carcinoma [31 & ]. The major benefit of ultrasound is that the technology is real time, so that information can be interpreted during the investigation. Frequency varies between 2 and 60 MHz with as a general rule: the higher the frequency, the higher the imaging resolution. However, image penetration depth decreases with increasing frequency. In the field of ultrasound, similar developments as with MRI are emerging. Detection rates of prostate cancer in greyscale ultrasound are low, but when the outputs of several sequences are combined, the accuracy would presumably go up. Advances in the field of ultrasound imaging of the prostate include contrast-enhanced ultrasonography (CEUS) (Fig. 2) , elastography, shear-wave elastography, power Doppler, and histoscanning. A consensus meeting about the use of ultrasound modalities in focal therapy concluded that the ultrasonography alone was insufficiently accurate for patient selection in 2011 [32] . In the last years, however, much research has been done into different modalities of ultrasound, which gives the technology a multiparametric character. In the past, it has been suggested that end-fire ultrasonography probes have a higher detection rate than side-fire probes. A recent article by Rom et al. [33] showed that the cancer detection rate in transrectal ultrasound (TRUS) does not depend on the type of ultrasound probe used (end-fire probe 34.3% or side-fire probe 34.4%) in 300 patients. Contrast-enhanced ultrasonography with contrast-tuned imaging technology has a greater sensitivity (73.1%) and accuracy (83.7%) than conventional greyscale ultrasound (50.9 and 78.8%), and power Doppler (48.3 and 77.7%). This study was performed in 150 patients with targeted biopsy as an endpoint [20] . Another prospective study investigated the hypothesis whether pretreatment with dutasteride would improve the detection rate of CEUS-guided biopsies. ROC analysis showed that CEUS increased the detection of cancer compared with greyscale ultrasound (sensitivity went up from 0.60 to 0.64 for all lesions). For high-grade lesions, however, sensitivity improved from 0.74 to 0.80. These numbers were even higher for high-grade lesions with more than 50% core involvement (0.83-0.90). Dutasteride pretreatment did not improve the detection rate [34] . Zalesky et al. [35] described an area under the ROC curve of 0.776 for power Doppler compared to 0.67 for normal greyscale, indicating that the sensitivity and specificity for power Doppler is significantly higher than greyscale ultrasound. This prospective study consisted of 146 patients. Brock et al. [22] described in 2012 in a prospective study of 353 patients that real-time elastographyguided biopsies revealed more prostate cancer (sensitivity 60.8 and specificity 68.4 ) than greyscale ultrasound-guided biopsies (sensitivity 15 and specificity 92.3). Simmons et al. [21] described the diagnostic accuracy of histoscanning. A total of 31 patients were included and the results were compared to radical prostatectomy. Sensitivity of 93% was found. A novelty in the field of elastography is the invention of shear-wave elastography. In shear-wave elastography, the ultrasound probe automatically generates standardized pressure waves, instead of depending on the pressure wave manually generated by the physician. In a prospective study of 53 patients, Barr et al. [23 && ] demonstrated a sensitivity of 96.2% with a specificity of 96.2%, positive predictive value (PPV) of 69.4, and negative predictive value (NPV) of 99.6 in patients with elevated PSA and abnormal digital rectal examination (DRE). Combining the outputs of these different ultrasound modalities into a standardized, automated multiparametric TRUS (mpTRUS) can be very promising for the diagnostic accuracy of ultrasound. Combined data on sensitivity and specificities of the different ultrasonography modalities can be found in Table 1 .
IMAGING FOR TREATMENT GUIDANCE
The goal of imaging during treatment guidance is to get the modality of focal therapy to the targeted area. For this, real-time orientation is essential. An ideal combination would be the high resolution and contrast of mpMRI with the real-time feedback of ultrasound.
There have been some recent advances in the field. Traditionally, ultrasound is the technology most used as a treatment-guidance modality in focal therapy. However, MRI-guided technologies are used more and more frequently. In 2012, Lindner et al. [36] described the first case of MRIguided high-frequency focused ultrasound (HIFU) ablation of prostate cancer. The major advantage of the procedure is that the tumor can be accurately targeted with small margins on MRI and the ablation zone can be accurately monitored during treatment. Disadvantage is that the technique is time-consuming. Bomers et al. [37 & ] provided an overview of MRI-guided focal technologies in 2012. Conclusions of this review article were that currently MRI-guided laser ablation and MRI-guided HIFU are the most promising options for focal treatment of the prostate in patients with prostate cancer. Other techniques -that is, cryosurgery, microwave ablation, and radiofrequency ablationare, for several and different reasons, less suitable for MRI-guided focal therapy of the prostate. A relatively new technology for image-guided thermal focal therapy is MR thermometry. With this technology, the temperature of tissue can be exactly monitored during ablative therapy. Partanen et al. [38] investigated the technology in dogs using transurethralfocused ultrasound monitored by MR thermometry. The technology rendered well tolerated and promising for use in humans. In 2013, Kuru et al. [39] demonstrated the accuracy of TRUS-MRI fused transperineal prostate biopsies. They proved a high detection rate of clinically significant tumors using this technology. A TRUS-MRI elastic fusion technology with excellent accuracy was also demonstrated by Ukimura et al. [40] in 2012. It is expected that TRUS-MRI fusion will gain field not only in targeted biopsy, but also in focal therapy treatment guidance in future. Results of the first use of TRUS-MRI fusion in focal therapy guidance are already emerging [41] .
IMAGING FOR FOLLOW-UP
Imaging for follow-up after focal therapy should ideally be fast, accurate, insensitive to treatment artifacts, and should be able to distinguish ablated area from tumorous tissue. The images should be comparable to previous imaging, to accurately detect recurrent and residual lesions. Ideally, the technology is minimally invasive, because imaging for follow-up has to be done repetitively.
There is little evidence about imaging in the follow-up after focal therapy of the prostate. Last year, a consensus project was set up along a 45-member panel of urologists and radiologists, and it was decided that follow-up of focal therapy should start with a mpMRI after 6 months, followed by a yearly mpMRI. mpMRI findings should be confirmed by targeted biopsy before retreatment [16 & ]. Few studies have been done on imaging modalities in the follow-up after focal therapy. One of these studies is a retrospective work by Punwani et al. [42] in 2012, in which 26 patients had a DCE-MRI and targeted biopsy of the prostate after whole-gland HIFU treatment. Sensitivity ranged between 73 and 87% among three readers, whereas specificity ranged between 73 and 82%. These results were comparable with prebiopsy PSA levels. A retrospective study with MRSI showed that most recurrences after focal radiation therapy occur at the same site as the dominant primary tumor at baseline. This suggests that supplementary focal therapy aimed at enhancing the lesions would be a rational addition to management [43] . Del Vescovo et al. [44 & ] evaluated DCE-MRI in a prospective study in 25 patients. In all patients, a rim of enhancement alongside the targeted area was observed on DCE-MRI, 1 month after treatment, which typically disappeared on later DCE-MRIs. Four months after treatment, the prostate had significantly reduced volume (average 61% volume reduction). Decision support systems (DSS) for mpMRI of the prostate are being designed to make reading more standard and less objective. The DSS provides a probability map for peripheral zone prostate tumors based on endorectal mpMRI. These probability maps may aid in reaching a higher accuracy and more comparable outcomes in the follow-up of focal therapies [45] .
CONCLUSION
State-of-the-art imaging in all phases of focal therapy is essential for treatment safety. In patient selection, treatment guidance, and follow-up, different aspects of imaging are important. Not only a high PPV is required, but also a high NPV to rule out significant cancer in other parts of the prostate. mpMRI is an imaging technology with high imaging resolution and contrast. This makes it an excellent technology for patient selection and treatment planning and follow-up. Ultrasound has the unique property of real-time image acquisition. This makes it an excellent technology for real-time treatment guidance.
There are multiple novelties in these two platforms that have increased the accuracy considerably. Examples in ultrasound are CEUS, elastography, shear-wave elastography, and histoscanning. In mpMRI, these advantages consist of multiple sequences combined to one image (mpMRI) and MR thermometry. Standardization of mpTRUS and mpMRI is of paramount importance. There is much to gain in these two fields. Imaging accuracy of the two platforms is comparable. Standardization in conduct and interpretation, 3D reconstruction, and fusion of the two platforms can bring focal therapy a step closer to the standard of care.
